Complementary measures for promoting insulin sensitivity in skeletal muscle

Medical Hypotheses

Volumn 51, Issue 6, 1998, Pages 451-464

  McCarty, M F ^a  

^a Nutrition 21 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CHROMIUM PICOLINATE; DIACYLGLYCEROL; DIACYLGLYCEROL KINASE; FATTY ACID; FISH OIL; INSULIN; INSULIN RECEPTOR; METFORMIN; PHOSPHATIDATE PHOSPHATASE; PROTEIN KINASE C; SULFONYLUREA; TROGLITAZONE; VANADYL SULFATE;

ARTICLE; EXERCISE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SYNDROME X; WEIGHT REDUCTION;

EID: 0032447176     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90065-2     Document Type: Article

References (193)

1. 1. Reaven G M. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. 2. Laakso M, Edelman S V, Brechtel G, Baron A D. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. J Clin Invest 1990; 85: 1844-1852.
3. 3. Baron A D, Steinberg H O, Chaker H et al. Insulin-mediating skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 1995; 96: 786-792.
4. 4. DeFronzo R A, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
5. 5. Björntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991; 14: 1132-1143.
6. 6. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NTDDM. Diabetes 1996; 45: 3-10.
7. 7. Bolinder J, Kager L, Östman J, Arner P. Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes 1983; 32: 117-123.
8. 8. Boden G, Chen X, Ruiz J et al. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994; 93: 2438-2446.
9. 9. Fukagawa N K, Anderson J W, Hageman G et al. High-carbohydrate, high-fiber diets increase peripheral insulin sensitivity in healthy young and old adults. Am J Clin Nutr 1990; 52: 524-528.
10. 10. Singh I. Low fat diet and therapeutic doses of insulin in diabetes mellitus. Lancet 1955; i: 422-425.
11. 11. Kiehm T G, Anderson J W, Ward K. Beneficial effects of a high carbohydrate, high fiber diet on hyperglycemic diabetic men. Am J Clin Nutr 1976; 29: 895-899.
12. 12. Barnard R J, Massey M R, Cherny S et al. Long term use of a high-complex carbohydrate, high fiber, low fat diet and exercise in the treatment of NIDDM patients. Diabetes Care 1983; 6: 268-273.
13. 13. Trowell H C. Non-infective Disease in Africa. London: Edward Arnold, 1960.
14. 14. Trowell H C, Burkitt D P, eds. Western Diseases: Their Emergence and Prevention. Cambridge, MA: Harvard University Press, 1981.
15. 15. Storlein L H, James D E, Burleigh K M et al. Fat feeding causes wide-spread in vivo insulin resistance, decreased energy expenditure and obesity in the rat. Am J Physiol 1986; 251: E576-E583.
16. 16. Storlien L H, Kraegen E W, Chisholm D J et al. Fish oil prevents insulin resistance induced by high fat feeding. Science 1987; 237: 885-888.
17. 17. Storlien L H, Jenkins A B, Chisholm D J et al. Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and ω-3 fatty acids in muscle phospholipid. Diabetes 1991; 40: 280-289.
18. 18. Mouratoff G J, Carroll N V, Scott E M. Diabetes mellitus in Eskimos. J Am Med Assoc 1967; 199: 961-966.
19. 19. Popp-Snijders C, Scheuten J A, Heine R J et al. Dietary supplementation of omega-3 polyunsaturated fatty acids improves insulin sensitivity in non-insulin-dependent diabetes. Diabetes Res 1987; 4: 141-147.
20. 20. Fasching P, Ratheiser K, Waldhäusl W et al. Metabolic effects of fish-oil supplementation in patients with impaired glucose tolerance. Diabetes 1991; 40: 583-589.
21. 21. Glauber H, Wallace P, Griver K, Brechtel G. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Int Med 1988; 108: 663-668.
22. 22. Kasim S E, Stern B, Khilnani S et al. Effects of omega-3 fish oils on lipid metabolism, glycemic control, and blood pressure in type II diabetic patients. J Clin Endocrinol Metab 1988; 67: 1-5.
23. 23. Sorisky A, Robbins D C. Fish oil and diabetes. The net effect. Diabetes Care 1989; 12: 302-304.
24. 24. Thorburn A W, Storlein L H, Jenkins A B et al. Fructoseinduced in vivo insulin resistance and elevated plasma triglyceride levels in rats. Am J Clin Nutr 1989; 49: 1155-1163.
25. 25. Storlien L H, Oakes N D, Pan D A et al. Syndromes of insulin resistance in the rat. Inducement by diet and amelioration with benfluorex. Diabetes 1993; 42: 457-462.
26. 26. Turner J L, Bierman E L, Brunzell J D, Chait A. Effect of dietary fructose on triglyceride transport and glucoregulatory hormones in hypertriglyceridemic men. Am J Clin Nutr 1979; 32: 1043-1050.
27. 27. Singh V N, Brin M. Fructose ingestion does not affect serum lipids in human subjects. Am J Clin Nutr 1981; 34: 1630-1631.
28. 28. Hallfrisch J, Reiser S, Prather E S. Blood lipid distribution of hyperinsulinemic men consuming three levels of fructose. Am J Clin Nutr 1983; 37: 740-748.
29. 29. Abbott W G H, Lillioja S, Young A A et al. Relationships between plasma lipoprotein concentrations and insulin action in an obese hyperinsulinemic population. Diabetes 1987; 36: 897-904.
30. 30. Rodnick K J, Haskell W L, Swislocki A L M et al. Improved insulin action in muscle, liver, and adipose tissue in physically trained human subjects. Am J Physiol 1987; 253: E489-E495.
31. 31. Tonino R P. Effect of physical training on the insulin resistance of aging. Am J Physiol 1989; 256: E352-E356.
32. 32. Hurley B F, Nemeth P M, Martin W H III et al. Muscle triglyceride utilization during exercise: effect of training. J Appl Physiol 1986; 60: 562-567.
33. 33. Gorski J. Muscle triglyceride metabolism during exercise. Can J Physiol Pharmacol 1992; 70: 123-131.
34. 34. Maggs D G, Jacob R, Rife F et al. Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricep muscle and adipose tissue. J Clin Invest 1995; 96: 370-377.
35. 35. Falholt K, Jensen I, Lindkaer Jensen S et al. Carbohydrate and lipid metabolism of skeletal muscle in type 2 diabetic patients. Diabetic Med 1988; 5: 27-31.
36. 36. Oscai L B, Essig D A, Palmer W K. Lipase regulation of muscle triglyceride hydrolysis. J Appl Physiol 1990; 69: 1571-1577.
37. 37. McCarty M F. Reduction of free fatty acids may ameliorate risk factors associated with abdominal obesity. Med Hypotheses 1995; 44: 278-286.
38. 38. Randle P J, Kerbey A L, Espinal J. Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones. Diab/Metab Rev 1988; 4: 623-638.
39. 39. Felber J-P, Ferrannini E, Golay A et al. Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes 1987; 36: 1341-1350.
40. 40. Acheson K J, Schutz Y, Bessard T et al. Nutritional influences on lipogenesis and thermogenesis after a carbohydrate meal. Am J Physiol 1984; 246: E62-E70.
41. 41. Hellerstein M K, Christiansen M, Kaempfer S et al. Measurement of de novo hepatic lipogenesis in humans using stable isotopes. J Clin Invest 1991; 87: 1841-1852.
42. 42. Eckel R H, Hanson A S, Chen A Y et al. Dietary substitution of medium-chain triglycerides improves insulin-mediated glucose metabolism in NIDDM subjects. Diabetes 1992; 41: 641-647.
43. 43. Bratusch-Marrain P R, DeFronzo R A. Failure of hyperketonemia to alter basal and insulin-mediated glucose metabolism in man. Horm Metabol Res 1986; 18: 185-189.
44. 44. Beylot M, Khalfallah Y, Riou J P et al. Effects of ketone bodies on basal and insulin-stimulated glucose utilization in man. J Clin Endocrinol Metab 1986; 63: 9-15.
45. 45. Paolisso G, Tataranni P A, Foley J E et al. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995; 38: 1213-1217.
46. 46. Nishizuka Y. The family of protein kinase C for signal transduction. J Am Med Assoc 1989; 262: 1826-1833.
47. 47. Osada S-I, Mizuno K, Saido T C et al. A new member of the protein kinase C family, nPKCθ, predominantly expressed in skeletal muscle. Molec Cell Biol 1992; 12: 3930-3938.
48. 48. Donnelly R, Reed M J, Azhar S, Reaven G M. Expression of the major isoenzyme of protein kinase-C in skeletal muscle, nPKC theta, varies with muscle type and in response to fructose-induced insulin resistance. Endocrinology 1994; 135: 2369-2374.
49. 49. Schmitz-Peiffer C, Brown C L, Oakes N D et al. Alterations in the expression and cellular localization of protein kinase C isozymes ∈ and θ are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes 1997; 46: 169-178.
50. 50. Heydrick S J, Ruderman N B, Kurowski T G et al. Enhanced stimulation of diacylglycerol and lipid synthesis by insulin in denervated muscle. Diabetes 1991; 40: 1707-1711.
51. 51. Takayama S, White M F, Lauris V, Kahn C R. Pnorbol esters modulate insulin receptor phosphorylation and insulin action in cultured hepatoma cells. Proc Natl Acad Sci 1984; 81: 7797-7801.
52. 52. Takayama S, White M F, Kahn C R. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. J Biol Chem 1988; 263: 3440-3447.
53. 53. Lewis R E, Cao L, Perregaux D, Czech M P. Threonine 1336 of the human insulin receptor is a major target for phosphorylation by protein kinase C. Biochemistry 1990; 29: 1807-1813.
54. 54. Considine R V, Caro J F. Protein kinase C: mediator of inhibitor of insulin action? J Cell Biochem 1993; 52: 8-13.
55. 55. Bollag G E, Roth R A, Beaudoin J et al. Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity. Proc Natl Acad Sci 1986; 83: 5822-5824.
56. 56. Pillay T S, Whittaker J, Siddle K. Phorbol ester-induced down-regulation of protein kinase C potentiates insulin receptor tyrosine autophosphorylation: evidence for a major constitutive role in insulin receptor regulation. Biochem Soc Trans 1990; 18: 494-495.
57. 2+-and phospholipid-activated protein kinase (protein kinase C). J Biol Chem 1984; 259: 8743-8747.
58. 58. Kellerer M, Seffer E, Muschack J et al. TPA inhibits insulin stimulated PIP hydrolysis in fat cell membranes: evidence for modulation of insulin dependent phospholipase C by protein kinase C. Biochem Biophys Res Comm 1990; 172: 446-454.
59. 59. Saltiel A R, Fox J A, Sherline P, Cuatrecasas P. Insulin-stimulated hydrolysis of a novel glycolipid generates modulators of cAMP phosphodiesterase. Science 1986; 233: 967-972.
60. 60. Okumura K, Akiyama N, Hashimoto H et al. Alteration of 1,2-diacylglycerol content in myocardium from diabetic rats. Diabetes 1988; 37: 1168-1172.
61. 61. Craven P A, DeRubertis F R. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose. J Clin Invest 1989; 83: 1667-1675.
62. 62. Lee T-S, Saltsman K A, Ohashi H, King G L. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complication. Proc Natl Acad Sci 1989; 86: 5141-5145.
63. 63. Wolf B A, Williamson J R, Easom R A et al. Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. J Clin Invest 1991; 87: 31-38.
64. 64. Tesfamariam B, Brown M L, Cohen R A. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 1991; 87: 1643-1648.
65. 65. Inoguchi T, Battan R, Handler E et al. Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci 1992; 89: 11059-11063.
66. 66. Xiang H, McNeill J H. Protein kinase C activity is altered in diabetic rat hearts. Biochem Biophys Res Comm 1992; 187: 703-710.
67. 67. DeRubertis F R, Craven P A. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 1994; 43: 1-8.
68. 68. Ishii H, Jirousek M R, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996; 272: 728-731.
69. 69. Müller H K, Kellerer M, Ermel B et al. Prevention by protein kinase C inhibitors of glucose-induced insulin-receptor tyrosine kinase resistance in rat fat cells. Diabetes 1991; 40: 1440-1448.
70. 70. Caro J F, Sinha M K, Raju S M et al. Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. J Clin Invest 1987; 79: 1330-1337.
71. 71. Arner P, Pollare T, Lithell H, Livingston J N. Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 437-440.
72. 72. Maegawa H, Shigeta Y, Egawa K, Kobayashi M. Impaired autophosphorylation of insulin receptors from abdominal skeletal muscles in non-obese subjects with NIDDM. Diabetes 1991; 40: 815-819.
73. 73. Häring H U. The insulin receptor: signalling mechanism and contribution to the pathogenesis of insulin resistance. Diabetologia 1991; 34: 848-861.
74. 74. Nagy K, Levy J, Grunberger G. High-fat feeding induces tissue-specific alteration in proportion of activated insulin receptors in rats. Acta Endocrinol 1990; 122: 361-368.
75. 75. Anderson C M, Henry R R, Knudson P E et al. Relative expression of insulin receptor isoforms does not differ in lean, obese, and noninsulin-dependent diabetes mellitus subjects. J Clin Endocrinol Metab 1993; 76: 1380-1382.
76. 76. Taylor S I. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992; 41: 1473-1490.
77. 77. Donnelly T E Jr, Birt D F, Sittler R et al. Dietary fat regulation of the association of protein kinase C activity with epidermal cell membranes. Carcinogenesis 1987; 8: 1867-1870.
78. 78. Choe M, Kris E S, Luthra R et al. Protein kinase C is activated and diacylglycerol is elevated in epidermal cells from Sencar mice fed high fat diets. J Nutr 1992; 122: 2322-2329.
79. 79. Craven P A, DeRubertis F R. Role of activation of protein kinase C in the stimulation of colonic epithelial proliferation by unsaturated fatty acids. Gastroenterology 1988; 95: 676-685.
80. 80. Chapkin R S, Gao J, Lee D-Y K, Lupton J R. Dietary fibers and fats alter rat colon protein kinase C activity: correlation to cell proliferation. J Nutr 1993; 123: 649-655.
81. 81. Steinberg H, Learning R, Cronin J et al. Elevated free fatty acids (FFA) levels impair endothelium dependent vasodilation. Diabetes 1996; 45(Suppl 2): 11A.
82. 82. Davda R K, Chandler L J, Guzman N J. Protein kinase C modulates receptor-independent activation of endothelial nitric oxide synthase. Eur J Pharmacol 1994; 266: 237-244.
83. 83. Kamata K, Chikada S, Umeda F, Kasuya Y. Effects of phorbol ester on vasodilation induced by endothelium-dependent or endothelium-independent vasodilators in the mesenteric arterial bed. J Cardiovasc Pharmacol 1995; 26: 645-652.
84. 84. Hirata K, Kuroda R, Sakoda T et al. Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension 1995; 25: 180-185.
85. 85. Ohara Y, Sayegh H S, Yamin J J, Harrison D G. Regulation of endothelial constitutive nitric oxide synthase by protein kinase C. Hypertension 1995; 25: 415-420.
86. 86. Steinberg H O, Brechtel G, Johnson A et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172-1179.
87. 87. Scherrer U, Randin D, Vollenweider P et al. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511-2515.
88. 88. Paolisso G, D'Amore A, Giugliano D et al. Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. Am J Clin Nutr 1993; 57: 650-656.
89. 89. Paolisso G, D'Amore A, Galzerano D et al. Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care 1993; 16: 1433-1437.
90. 90. Paolisso G, Di Maro G, Galzerao D et al. Pharmacological doses of vitamin E and insulin action in elderly subjects. Am J Clin Nutr 1994; 59: 1291-1296.
91. 91. Paolisso G, Gambardella A, Giugliano D et al. Chronic intake of pharmacological doses of vitamin E might be useful in the therapy of elderly patients with coronary heart disease. Am J Clin Nutr 1995; 61: 848-852.
92. 92. Tran K, Proulx P R, Chan A C. Vitamin E suppresses diacylglycerol (DAG) level in thrombin-stimulated endothelial cells through an increase of DAG kinase activity. Biochim Biophys Acta 1994; 1212: 193-202.
93. 93. Kunisaki M, Bursell S-E, Umeda F et al. Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes 1994; 43: 1372-1377.
94. 94. Kunisaki M, Bursell S-E, Clermont A C et al. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol 1995; 269: E239-E246.
95. 95. Lee I-K, Koya D, Ishii H, King G L. Vitamin E (vit E) prevents the hyperglycemia induced activation of diacylglycerol (DAG)-protein kinase C (PKC) pathway in vascular smooth muscle cell by an increase of DAG kinase activity. Diabetes 1996; 45(Suppl2): 64A.
96. 96. Koya D, Lee I-K, Ishii H, Bursell S-E. Vitamin E normalized glomerular hyperfiltration and protein kinase C activation by increasing diacylglycerol kinase in diabetic rats. Diabetes 1996; 45(Suppl2): 205A.
97. 97. Paolisso G, D'Amore A, Balbi V et al. Plasma vitamin C affects glucose homeostasis in healthy subjects and in noninsulin-dependent diabetics. Am J Physiol 1994; 266: E261-E268.
98. 98. Som S, Raha C, Chatterjee I B. Ascorbic acid: a scavenger of superoxide radical. Acta Vitaminol Enzymol 1983; 5: 243-250.
99. 99. Ting H H, Timimi F K, Boles K S et al. Vitamin C improves endothelium-dependent vasodilation in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1996; 97: 22-28.
100. 100. Matsubara T, Ziff M. Superoxide anion release by human endothelial cells: synergism between a phorbol ester and a calcium ionophore. J Cell Physiol 1986; 127: 207-210.
101. 101. Murphy H S, Shayman J A, Till G O et al. Superoxide responses of endothelial cells to C5a and TNF-α: divergent signal transduction pathways. Am J Physiol 1992; 263: L51-L59.
102. 102. Mügge A, Elwell J H, Peterson T E, Harrison D G. Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol 1991; 260: C219-C225.
103. 103. Hattori Y, Kawaskai H, Abe K, Kanno M. Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol 1991; 261: H1086-H1094.
104. 104. Beckman J S, Beckman T W, Chen J et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci 1990; 87: 1620-1624.
105. 105. Marsh J B, Topping D L, Nestel P J. Comparative effects of dietary fish oil and carbohydrate on plasma lipids and hepalic activities of phosphatidate phosphohydrolase, diacylglycerol acyltransferase and neutral lipase activities in the rat. Biochim Biophys Acta 1987; 922: 239-243.
106. 106. Wong S-H, Marsh J B. Inhibition of apolipoprotein secretion and phosphatidate phosphohydrolase activity by eicosapentaenoic and docosahexaenoic acids in the perfused rat liver. Metabolism 1988; 37: 1177-1181.
107. 107. Surette M E, Whelan J, Broughton K S, Kinsella J E. Evidence for mechanisms of the hypotriglyceridemic effect of n-3 polyunsaturated fatty acids. Biochim Biophys Acta 1992; 1126: 199-205.
108. 108. McCarty M F. Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion - the 'PKC syndrome'. Med Hypotheses 1996; 46: 191-221.
109. 109. Mimura K, Umeda F, Hiramatsu S et al. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabetic Med 1994; 11: 685-691.
110. 110. Nolan J J, Ludvik B, Beerdsen P et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-1193.
111. 111. Whitcomb R W, Saltiel A R. Thiazolidinediones. Exp Opin Invest Drugs 1995; 4: 1299-1309.
112. 112. Iwamoto Y, Kosaka K, Kuzuya T et al. Effects of troglitazone. A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19: 151-156.
113. 113. Kumar S, Boulton A J M, Beck-Nielsen H et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39: 701-709.
114. 114. Kobayashi M, Iwanishi M, Egawa K, Shigeta Y. Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 1992; 41: 476-483.
115. 115. Iwanishi M, Kobayashi M. Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats. Metabolism 1993; 42: 1017-1021.
116. 116. Kellerer M, Kroder G, Tippmer S et al. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 1994; 43: 447-453.
117. 117. Ikeda H, Taketomi S, Sugiyama Y et al. A new oral hypoglycemic agent, 5-[4-[2-(5-ethyl-2-pyrudul)ethoxyl]benzyl] 2,4-thiazolidinedione (AD-4833, U-72,107E, pioglitazone). I. Effects on glucose and lipid metabolism in normal and insulin resistant animals. Arzneim-Forsch 1990; 40: 156-162.
118. 118. Mertz W. Chromium in biological systems. Physiol Rev 1969; 49: 163-239.
119. 119. Mertz W. Chromium in human nutrition: a review. J Nutr 1993; 123: 626-633.
120. 120. Schroeder H A. Chromium deficiency in rats: a syndrome simulating diabetes mellitus with retarded growth. J Nutr 1966; 88: 439-445.
121. 121. Jeejeebhoy R K, Chu R C, Marliss E B et al. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr 1977; 30: 531-538.
122. 122. Anderson R A, Polansky M M, Bryden N A et al. Chromium supplementation of human subjects: effects on glucose, insulin and lipid parameters. Metabolism 1983; 32: 894-899.
123. 123. Anderson R A, Polansky M M, Bryden N A, Canary J J. Supplemental chromium effects on glucose, insulin, glucagon and urinary chromium losses in subjects consuming controlled low-chromium diets. Am J Clin Nutr 1991; 54: 909-916.
124. 124. Sherman L, Glennon J A, Brech W J et al. Failure of trivalent chromium to improve hyperglycemia in diabetes mellitus. Metabolism 1968; 17: 439-442.
125. 125. Uusitupa M I J, Kumpulainen J T, Voutilainen E et al. Effect of inorganic chromium supplementation on glucose tolerance, insulin response and serum lipids in noninsulin-dependent diabetics. Am J Clin Nutr 1983; 38: 404-410.
126. 126. Abraham A S, Brooks B A, Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin dependent diabetes. Metabolism 1992; 41: 768-771.
127. 127. Anderson R A, Cheng N, Bryden N et al. Beneficial effects of chromium for people with type II diabetes. Diabetes 1996; 45(Suppl 2): 124A.
128. 128. Cefalu W T, Bell-Farrow A D, Wang Z Q et al. The effect of chromium supplementation on carbohydrate metabolism and body fat distribution (abstract). Diabetes 1997, in press.
129. 129. Anderson R A, Polansky M M, Bryden N A et al. Effects of supplemental chromium on patients with symptoms of reactive hypoglycemia. Metabolism 1987; 36: 351-355.
130. 130. Berrio L F, Southern L L, Fernandez J M et al. Effect of dietary chromium tripicolinate on insulin binding in isolated pig fat cells and erythrocyte ghosts. FASEB J 1995; 9: A449.
131. 131. Ward T L, Berrio L F, Southern L L et al. In-vivo and in-vitro evaluation of chromium tripicolinate on insulin binding in pig liver cell plasma membranes. FASEB J 1994; 8: A194.
132. 132. Evans G W, Bowman T D. Chromium picolinate increases membrane fluidity and rate of insulin internalization. J Inorg Biochem 1992; 46: 243-250.
133. 133. Lee J-K, Tam J W O, Tsai M-J, Tsai S Y. Identification of cis-and trans-acting factors regulating the expression of the human insulin receptor gene. J Biol Chem 1992; 267: 4638-4645.
134. 134. Chen H, Walker G E, Taylor S I, McKeon C. Proximal enhancer of the human insulin receptor gene binds the transcription factor Sp1. Diabetes 1994; 43: 884-889.
135. 135. Brunetti A, Foti D, Goldfine I D. Identification of unique nuclear regulatory proteins for the insulin receptor gene, which appear during myocyte and adipocyte differentiation. J Clin Invest 1993; 92: 1288-1295.
136. 136. Webster N J G, Kong Y, Cameron K E, Resnik J L. An upstream element from the human insulin receptor gene promoter contains binding sites for C/EBPβ and NF-1. Diabetes 1994; 43: 305-312.
137. 137. Brichard S M, Bailey C J, Henquin J-C. Marked improvement of glucose homeostasis in diabetic oblob mice given oral vanadate. Diabetes 1990; 39: 1326-1332.
138. 138. Pugazhenthi S, Khandelwal R L. Insulinlike effects of vanadate on hepatic glycogen metabolism in nondiabetic and streptozocin-induced diabetic rats. Diabetes 1990; 39: 821-827.
139. 139. Cam M C, Cros G H, Serrao J-J et al. In vivo antidiabetic actions of naglivan, an organic vanadyl compound in streptozotocin-induced diabetes. Diabetes Res Clin Pract 1993; 20: 111-121.
140. 140. Domingo J L, Gomez M, Llobet J M et al. Oral vanadium administration to streptozotocin-diabetic rats has marked negative side-effects which are independent of the form of vanadium used. Toxicology 1991; 66: 279-287.
141. 141. Swarup G, Cohen S, Garbers D L. Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem Biophys Res Comm 1982; 107: 1104-1109.
142. 142. Boden G, Chen X, Ruiz J et al. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with noninsulin-dependent diabetes mellitus. Metabolism 1996; 45: 1130-1135.
143. 143. Halberstam M, Cohen N, Shlimovich P et al. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 1996; 45: 659-666.
144. 144. Carpenter G. Vanadate, epidermal growth factor and the stimulation of DNA synthesis. Biochem Biophys Res Comm 1981; 102: 1115-1121.
145. 145. Klarlund J K. Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosine in proteins. Cell 1985; 41: 707-717.
146. 146. Foley J E. Mechanisms of impaired insulin action in isolated adipocytes from obese and diabetic subjects. Diab/Metab Rev 1988; 4: 487-505.
147. 147. Fraze E, Donner C C, Swislocki A L M et al. Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrinol Metab 1985; 61: 807-811.
148. 148. Chen Y-D I, Golay A, Swislocki A L M, Reaven G M. Resistance in insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 64: 17-21.
149. 149. Reaven G M, Hollenbeck C, Jeng C-Y et al. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988; 37: 1020-1024.
150. 150. Ferrannini E, Barret E J, Bevilacqua S, DeFronzo R A. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983; 72: 1737-1747.
151. 151. Rebrin K, Steil G M, Getty L, Bergman R N. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 1995; 44: 1038-1045.
152. 152. Rebrin K, Steil G M, Mittelman S D, Bergman R N. Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs. J Clin Invest 1996; 98: 741-749.
153. 153. Thorens B, Yu Y-J, Leahy J L, Weir G C. The loss of GLUT2 expression by glucose-unresponsive β cells of db/db mice is reversible and is induced by the diabetic environment. J Clin Invest 1992; 90: 77-85.
154. 154. Lee Y, Hirose H, Ohneda M et al. β-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-β-cell relationships. Proc Natl Acad Sci 1994; 91: 10878-10882.
155. 155. Unger R H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Diabetes 1995; 44: 863-870.
156. 156. Luo J, Rizkalla S W, Boillot J et al. Dietary (n-3) polyunsaturated fatty acids improve adipocyte insulin action and glucose metabolism in insulin-resistant rats: relation to membrane fatty acids. J Nutr 1996; 126: 1951-1958.
157. 157. Szalkowski D, White-Carrington S, Berger J, Zhang B. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 1995; 136: 1474-1481.
158. 158. Mertz W. Effects and metabolism of glucose tolerance factor. Nutr Rev 1975; 33: 129-135.
159. 159. Press R I, Geller J, Evans G W. The effect of chromium on serum cholesterol and apolipoprotein fractions in human subjects. West J Med 1990; 152: 41-45.
160. 160. Lee N A, Reasner C A. Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM. Diabetes Care 1994; 17: 1449-1452.
161. 161. Dulbecco A, Albenga C, Borretta G et al. Effect of acipimox on plasma glucose levels in patients with non-insulin-dependent diabetes mellitus. Curr Ther Res 1989; 46: 478-483.
162. 162. Stewart M W, Dyer R G, Alberti K G M M, Laker M F. The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia. Diabetic Med 1995; 12: 250-257.
163. 163. Worm D, Henriksen J E, Vaag A et al. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab 1994; 78: 717-721.
164. 164. Piatti P M, Monti L D, Davis S N et al. Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients. Diabetologia 1996; 39: 103-112.
165. 165. Jackson R A, Hawa M I, Jaspan J B et al, Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 1987; 36: 632-640.
166. 166. Shepherd M, Kushwaha R. Effect of metformin on basal and postprandial lipid and carbohydrate metabolism in NIDDM subjects. Diabetes 1994; 43(Suppl 1): 74A.
167. 167. Stumboll M, Nurjhan N, Perriello G et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554.
168. 168. Cusi K, Consoli A, DeFronzo R A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulindependent diabetes mellitus. J Clin. Endocrinol Metab 1996; 81: 4059-4067.
169. 169. Ciraldi T P, Gilmore A, Olefsky J M et al. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990; 39: 1056-1062.
170. 170. Groop L C. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-754.
171. 171. Clarke B F, Duncan L J P. Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics. Lancet 1968; i: 123-126.
172. 172. Clarke B F, Campbell I W. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. Br Med J 1977; 2: 1576-1578.
173. 173. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
174. 174. Jialal I, Fuller C J, Huet B A. The effect of α-tocopherol supplementation on LDL oxidation. A dose-response study. Arterioscler Thromb Vasc Biol 1995; 15: 190-198.
175. 175. Esterbauer H, Puhl H, Dieber-Rotheneder M et al. Effect of antioxidants on oxidative modification of LDL. Ann Med 1991; 23: 573-581.
176. 176. Gilbert V A, Zebrowski E J, Chan A C. Differential effects of megavitamin E on prostacyclin and thromboxane synthesis in streptozotocin-induced diabetic rats. Hormone Metab Res 1983; 15: 320-325.
177. 177. FitzGerald G A, Bush A R. Endogenous protacyclin and thromboxane biosynthesis during chronic vitamin E therapy in man. Ann NY Acad Sci 1982; 393: 209-211.
178. 178. Stampfer M J, Rimm E B. Epidemiologic evidence for vitamin E in prevention of cardiovascular disease. Am J Clin Nutr 1995; 62: 1365S-1369S.
179. 179. Hodis H N, Mack W J, LaBree L et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. J Am Med Assoc 1995; 273: 1849-1854.
180. 180. Stephens N G, Parsons A, Schofield P M et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge heart antioxidant study (CHAOS). Lancet 1996; 347: 781-786.
181. 181. Harats D, Dabach Y, Hollander G et al. Fish oil ingestion in smokers and nonsmokers enhances peroxidation of plasma lipoproteins. Atherosclerosis 1991; 90: 127-139.
182. 182. Simopoulos A P. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991; 54: 438-463.
183. 183. McVeigh G E, Brennan G M, Johnston G D et al. Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 33-38.
184. 184. McCarty M F. Fish oil may be an antidote for the cardiovascular risk of smoking. Med Hypotheses 1996; 46: 337-347.
185. 185. Bang H O, Dyerberg J, Sinclair H M. The composition of the Eskimo food in north western Greenland. Am J Clin Nutr 1980; 33: 2657-2661.
186. 186. Gapinski J P, Van Ruiswyk J V, Heudebert G R et al. Fish oil for restenosis after angioplasty: a meta-analysis. Ann Intern Med 1994; 120 (2 Suppl 1): 8-10.
187. 187. Abraham A S, Sonnenblick M, Eini M et al. The effect of chromium on established atherosclerotic plaques in rabbits. Am J Clin Nutr 1980; 33: 2294-2298.
188. 188. Abraham A S, Sonnenblick M, Eini M. The action of chromium on serum lipids and on atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 1982; 42: 185-195.
189. 189. Schroeder H A, Nason A P, Tipton I H. Chromium deficiency as a factor in atherosclerosis. J Chronic Dis 1970; 23: 123-142.
190. 190. Newman H A I, Leighton R F, Lanese R R et al. Serum chromium and angiographically determined coronary artery disease. Clin Chem 1978; 24: 541-544.
191. 191. Simonoff M, Llabador Y, Hamon C et al. Low plasma chromium in patients with coronary artery and heart disease. Biol Trace Element Res 1984; 6: 431-439.
192. 192. McCarty M F. A central role for protein kinase C overactivity in diabetic glomerulosclerosis - implications for prevention with antioxidants, fish oil, and ACE inhibitors. Med Hypotheses 1998; 50: 155-165.
193. 193. McCarty M F. Nitric oxide deficiency, leukocyte activation, and resultant ischemia are crucial to the pathogenesis of diabetic retinopathy/neuropathy - preventive potential of antioxidants, essential fatty acids, chromium, gingkgolides, and pentoxifylline. Med Hypotheses 1998; 50: 435-449.